Psilocybin molecule:

Image from PubChem

Psilocybin Clinical Trials

Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder

To see complete record on, please visit this link

Id: NCT04620759

Organisation Name: Johns Hopkins University

Overal Status: Recruiting

Start Date: April 14, 2021

Last Update: August 30, 2022

Lead Sponsor: Johns Hopkins University

Brief Summary: The purpose of this study is to determine whether psilocybin, a hallucinogenic drug, is effective in reducing depressive symptoms and amount of drinking in patients with co-occurring Major Depressive Disorder (MDD) and Alcohol Use Disorder (AUD).

  • Major Depressive Disorder
  • Alcohol Use Disorder

Total execution time in seconds: 1.2062430381775